

## Special Issue

# The Role of Microglia in Human Diseases

### Message from the Guest Editor

Microglia are the primary immune cells of the central nervous system (CNS), similar to peripheral macrophages. They produce a strong proliferative response (microgliosis) to pathogens by changing morphology and migrating to the site of infection, where they destroy pathogens and remove damaged cells. It would be very important to study microglia's involvement in promoting or limiting the pathogenesis of different neuronal diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, multiple sclerosis, X-linked adrenoleukodystrophy (X-ALD), lysosomal storage diseases (LSDs), etc. In this Special Issue, we invite manuscripts on the role of microglia in different CNS diseases, other infectious diseases such as HIV-1 and HAND, and additional microglial involvement in the pathogenesis of diverse diseases and therapy-based research studies/reviews.

### Guest Editor

Dr. Ana Borrajo

Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain

### Deadline for manuscript submissions

closed (31 March 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/170496](https://mdpi.com/si/170496)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).